that were related to ciprofloxacin by the treating doctors (personal communication). Apart from the seven patients reported here, we also followed up three patients who received ciprofloxacin inadvertently during the first trimester of pregnancy; one of these women has delivered a healthy baby who has had normal linear growth for first 6 months. Although we cannot make any definite conclusions from our limited data, we believe use of ciprofloxacin in patients with MDRREF in second-trimester and third-trimester pregnancies may be justified when no clearly safe and effective alternative is available.

Parvain Ahmad Kouli, Javed Iqbal Wani, Abdul Wahid
Department of Internal Medicine, Institute of Medical Sciences, Srinagar, 190011, Kashmir, India


Evidence for HIV-1 group O infection in Nigeria

Sit—Dada and colleagues (June 3, p 1436) report that no HIV-1 group O infection was found in Nigeria. We report here the preliminary data of a study in the Cross River state in Nigeria. This region, one of 30 Nigerian states, is located in the south-eastern part of the country and borders Cameroon. Most HIV-1 group O infections have been reported from Cameroon and a few cases from Gabon.1

Between 1992 and 1994, a total of 2083 serum samples were obtained for a sentinel surveillance study from pregnant women, patients with tuberculosis, infectious diseases, sexually transmitted disease, and commercial sex workers. Of these samples 183 were positive for HIV—ie, a positive reaction with the Wellscozyme HIV-1/HIV-2 test (Murex Diagnostics, UK) and HIVCHECK (Ortho Diagnostics, USA) tests; 87 were indeterminate for HIV antibodies—ie, only antibodies to gag and/or pol proteins by western blot; and 1813 were negative for HIV. All samples were tested for the presence of HIV-1 group O antibodies by an ELISA based on synthetic peptides derived from the V3 loop of the envelope proteins representing group O viruses (ANT70 and MVP5180).12 Samples reactive by ELISA were retested in a line immunassay (LIA), in which different biotinylated V3 peptides (consensus, MAL, ANT76, V1665, Gabonese HIV-1 group O isolate) and MVP5180 were applied as a Streptavidin complex in parallel lines on nylon strips (Innogenetics, Belgium). Samples reactive in ELISA and LIA were also retested on a specific western blot for the presence of antibodies to gp120 of HIV-1 ANT70, as previously described.12 12 of the 2083 serum samples were reactive in the V3 ELISA; ten had optical density (OD) values above the cut-off, and only two had a higher OD value (OD/cut-off ratio 3-5). The ten weakly reactive samples showed no reaction with the group O V3 peptides in LIA. One of the two other reactive samples had a reaction with the ANT70 peptide but reacted simultaneously with the consensus and the MAL peptide and had antibodies to the gp120 envelope proteins on a specific HIV-1 ANT70 western blot. The other serum with a high OD value in ELISA reacted on LIA only with the V3 peptides from group O with a strong reaction to the ANT70 peptide and a weaker reaction with the V1665 and MVP5180 V3 peptides, which clearly indicates the presence of HIV-1 group O infection. Both samples were from Nigerian AIDS patients. These preliminary data, in contrast with Dada and colleagues’ report, HIV-1 group O infection is present in Nigeria, especially in the Cross River state. Despite the geographic location of this state, bordering Cameroon, where a prevalence of up to 2% has been reported, we showed that HIV-1 group O prevalence was low. The spread of these viruses in this and other states of Nigeria should be examined to see whether strategies for blood screening and serodiagnosis need modification.

Claire Mulanga Kabeya, Eka Esu-Williams, Eko Eni, Martine Pesters, Eric Saman, Eric Delaporte
Laboratoire Rétrovirologie, ORSTOM, BP 5045, 34032 Montpellier, France; Laboratory of Biology, Université de Calabar, Nigeria; and Innogenetics, Ghent, Belgium

Surveillance of heterosexually acquired HIV infection and AIDS

Sit—For surveillance purposes, the US Centers for Disease Control and Prevention (CDC)1 have recently restricted the definition of heterosexually acquired HIV infection: heterosexual contract cases are those who report specific heterosexual contact with a person known to be HIV-infected, irrespective of his/her exposure category, or with a person at an increased risk of HIV infection—ie, intravenous drug users, male bisexuals, haemophiliacs, or other recipients of HIV-contaminated blood products. People from countries where heterosexual transmission is presumed to be the predominant mode of HIV transmission and those who have sex with a person from such countries are no longer reported in the USA as having acquired AIDS or HIV infection through heterosexual contact. The French Direction Générale de la Santé (DGS) has maintained this last category in the definition of heterosexually acquired HIV infection.1

The impact of various definitions of heterosexually acquired HIV infection has been evaluated in the hospital-based surveillance system of HIV infection in place in Aquitaine, south-western France (2-8 millions inhabitants), since 1985.1 HIV-positive patients aged 13 years or older who gave informed consent are reported by the participating physicians, whatever their clinical stage of infection. This system accounted for 84% of the cases of HIV infection diagnosed in the region from 1991 to 1993.1 Once reported all patients are included in the Aquitaine cohort, and all exposure categories are represented. Epidemiological data obtained by interview and from medical records were updated during follow-up. Heterosexually acquired infection were considered according to the CDC definition,1 the DGS definition,2 probable and possible cases, and two sub-categories of the no risk reported or identified category: probable cases are those subjects who report heterosexual
EDITORIAL
259  The final autonomy

COMMENTARY
260  US science on the slide  R Horton
260  Toxic gas trauma  M J World
261  AMA rewrites tobacco history  A Blum, H Wolinsky
262  Preventing AIDS: have we lost our way?  A R Lifson
263  On line for digital mammography  C J D'Orsi, A Karellas
263  Pott's paraplegia today  J D Miller

ARTICLES
265  Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients  Prostate Cancer Trialsists' Collaborative group
270  Manganese and chronic hepatic encephalopathy  D Krieger, S Krieger, O Jansen, P Giese, G Theilmann, W Elsner
274  3849+10 kb C→T mutation and disease severity in cystic fibrosis  R C Stern, C F Doershuk, M L Drumm
277  Donors' attitudes towards body donation for dissection  R Richardson, B Hurwitz

SHORT REPORTS
280  Objective passive-smoking indicators and respiratory morbidity in young children  C G Bakoula, Y J Kafritsa, G D Kavadias, D D Lazopoulos, M C Theodoridou, K P Maravelias, N S Matsaniotis
281  Association between clozapine response and allelic variation in 5-HT2A receptor gene  M Arranz, D Collier, M Sodhi, D Ball, G Roberts, J Price, P Sham, R Kerwin

GRAND ROUND
283  Raynaud's phenomenon  Report of a Meeting of Physicians and Scientists, University College London Medical School, London

PUBLIC HEALTH
290  Sarin poisoning in Matsumoto, Japan  H Morita, N Yanagisawa, T Nakajima, M Shimizu, H Hirabayashi, H Okudera, M Nozawa, Y Midoriikawa, S Mimura

PERSONAL PAPER
293  Practising obstetrics and gynaecology in areas with a high prevalence of HIV infection  D A A Verkuyl